Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

BUY
$12.63 - $24.47 $865,622 - $1.68 Million
68,537 Added 8.46%
878,275 $20.7 Million
Q3 2023

Oct 26, 2023

BUY
$10.86 - $17.62 $8.79 Million - $14.3 Million
809,738 New
809,738 $12.1 Million

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Emerald Mutual Fund Advisers Trust Portfolio

Follow Emerald Mutual Fund Advisers Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Mutual Fund Advisers Trust, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Mutual Fund Advisers Trust with notifications on news.